

3Q24 Results Presentation

November 13th, 2024



Disclaimer




This presentation includes forwardlooking statements and information related to the Company that reflect the current views and/or expectations of the Company and its Management relating to its performance, business and future events. The statements contained herein include, without limitation, any forwardlooking statement, estimates and projections of future results, performance and objectives, as well as terms such as "believe", "anticipate", "expect", "estimate", "project", among other similar expressions. Said statements are subject to risks, uncertainties and future events. We advise investors that many factors can cause actual results to differ materially from the plans, objectives, expectations, projections and intentions contained in this presentation.

In view of the foregoing risks and uncertainties, the forward-looking circumstances and events discussed herein may not occur, and the Company's future results may differ materially from those expressed or implied in these forward-looking statements. Forwardlooking statements involve risks and uncertainties and are not guarantees of future events. Investors should not make any investment decisions based on any forward-looking statements contained herein. Therefore, under no circumstances is the Company, its subsidiaries, board members, directors, agents or employees responsible before third parties (including investors) for any investment decision taken based on the information presented in this presentation, or for any damage resulting therefrom.

Market and competitive position information, including any market projections mentioned throughout this document, has been obtained from internal research, market surveys, public domain information and corporate publications. Although we have no reason to believe that any such information or reports are inaccurate in any material respect, we have not independently verified the competitive positions, market positions, growth rates or any other data provided by third parties or other industry publications. The Company is not responsible for the veracity of such information.

Certain percentages and other values included in this document have been rounded to facilitate presentation. Scales can appear in different proportions to optimize the demonstration. Therefore, the figures and charts presented may not represent the arithmetic sum and the appropriate scale of the figures that precede them and may differ from those presented in the financial statements.





01 Highlights of ***** the Quarter



Main highlights of 3Q24



The average ticket for **DE Undergrad**. segment increased 7.3% in 3Q24 vs. 3Q23, reflecting the new criteria to activate students, differentiated brand positioning strategy, and course mix;



Net Revenue increased by 8.8% in 3Q24 vs. 3Q23, driven by a good performance in the DE Undergraduate, Medical and Continuing Education segments;



Adjusted EBITDA growth of 9.9% in 3Q24, positively impacted by effective SG&A control and lower PDA levels;




Adjusted Net Income of R\$64.1 million in 3Q24, 76.3% higher than the same period last year.



DE Intake grew by 10.4% in 3Q24, reinforcing our competitive advantages




Total Intake | DE Undergraduate ⁽¹⁾ ('000) **10.4%** In absolute terms, the intake continues to show a solid



performance, with an emphasis on engaged students.⁽²⁾


Intake Breakdown




"Unengaged" students are no longer included in the student and net revenue base, as of 1Q24.









UNIASSELVI adopts criteria for activating UniCesumar students from 2024 onwards;


Note: Includes engaged and unengaged students. An engaged student is one with financial and/or academic commitment after enrolling. However, as of 2024, unengaged students are no longer included in the student base and does not contribute to net revenue. (1) Number of non-engaged students in 3Q23.



Solid geographic presence throughout Brazil, with good opportunities for further expansion and maturation of hubs



Strong expansion over the years, mainly in the southeast region



(1) Does not include three international hubs for UniCesumar and their respective students.





Opening of new hubs, taking quality higher education to communities that were previously deprived of it.

# of hubs (as of 3Q24)		LINICesumar	
South	284	260	544
South - PR	75	117	192
South - RS	120	79	199
South - SC	89	64	153
Southeast	402	526	928
Southeast - ES	24	14	38
Southeast - MG	118	162	280
Southeast - RJ	86	108	194
Southeast - SP	174	242	416
Midwest	371	345	716
North	161	109	270
Northeast	110	107	217
Total	1,328	1,347	2,675

Faster opening of new hubs

in locations where currently only one brand is offered

# of cities	3Q23	3Q24	Δ%
With Only one brand	703	673	-4.3%
With both brands	687	777	+13.1%
Total	1,390	1,450	+4.3%


(1) Does not include three international hubs for UniCesumar.



Average ticket growth in the DE undergraduate segment, even in a more challenging competitive environment




Average Ticket | DE Undergraduate (R\$)



Ke continue to adjust ticket prices even in a challenging economic and competitive environment.


Intake Breakdown | DE Undergraduate





(R\$MM)

Business diversification boosting Net Revenue



Undergraduate

* Focus on the digital education undergraduate segment, which continues to grow consistently and has a larger engaged base;

🔆 Net Medical Revenue driven by the maturing of the Medicine unit Corumbá;

3Q23

 \neq The performance of the Continuing Education Courses demonstrates the potential of this avenue for growth.

(ex-Medicine)


3Q24

VTRU B3 LISTED NM



Focus on Digital Education, as well as a solid Medical business and great potential in Continuing Education





Undergraduate

(ex-Medicine)


Education



DE Undergraduate: growth driven by the value proposition generated for students and a unique positioning among both brands




DE Undergraduate Net Revenue (R\$MM)



Resilience and differentiation of our academic model and maturation of our operational hubs


(1) Source: INEP 2022 Census.

Combined Market Share Growth ⁽¹⁾ (Market Share of private DE Undergraduate students, in %)⁽¹⁾



Vitru Player 1 Player 2 Player 3 Player 4 Player 5


Evolution of enrollment in private education - on-campus and digital education $^{\left(1\right)}$







Maringá Medical School: the largest in the South Region (298 seats in a single campus) at an upscale location



(1) Does not include seats for PROUNI and FIES; (2) Considering the Preliminary Course Concept (CPC 2019); (3) Does not include 50 potential additional seats in Corumbá.






~1,3 million college graduates every year ⁽¹⁾ Significant potential to offer Continuing Education courses, leveraging on Vitru's capabilities in the Undergraduate Digital Education business ~7.7million high school graduates per year ⁽¹⁾

At the age of 16+ and ready to take up employment in the job market as **technicians or skilled workers**

Authorized seats in federal-level technical courses

Educations Groups	# Seats	% Seats
Vitru	156,142	42.8%
Player 1	101,986	28.0%
Player 2	46,052	12.6%
Player 3	31,670	8.7 %
Others	28,691	7.9%



(1) Source: INEP 2023 Census. Average of the last 5 INEP Census 2023



The Transformation Program will be the driving force behind Vitru's next phase of growth






- Ensure greater competitive advantages in the core business and strengthen operations in adjacent areas.
- Build value by sustaining above-market growth and striving for excellence in terms of business, students and employees.
- Maximize margin gains in a challenging scenario through operational improvements and by exploring highly profitable opportunities.




Priority agenda for the CEO and Board of Directors







Continuous, long-term effort



Based on strategic pillars, the Transformation Program will be unfolded for its execution



Strategic pillars

Involving core business, adjacent areas, in-person courses and key enablers



Initiatives

Unfolded into multiple projects that will address the Institution's main growth levers



Technology and digitalization

Important focus on strengthening our technological platforms and providing a better digital experience

Dedicated Transformation Office

External support for organizing, monitoring generated value and following up on team performance







This award reinforces Vitru's role as a leader in academic innovation in Brazil, demonstrating our ongoing commitment to providing high-quality education with modern methodologies that respond to the challenges of the 21st century.



We are among the top 100 companies leading open innovation in Brazil, building strategic partnerships that drive our growth and continuous innovation.




This seal reinforces Vitru's commitment to educational excellence and the constant search for innovations that enhance the student experience and the development of our teachers.


02 Financial Results 3Q24 🔆


Sustainable growth in the main segments in which we operate, reinforcing our business strategy






Medicine Undergraduate Net Revenue






Continuing Education







Composition of Costs and Expenses (R\$MM)



3Q23

3Q24


% da ROL	3Q23	3Q24	∆ %	9M23	9M24	∆ %
Cost of Services	30.1%	32.5%	2.5 p.p.	29.7%	29.6%	(-0.1 p.p.)
G&A	6.9%	6.6%	(-0.3 p.p.)	5.7%	5.9%	0.2 p.p.
Selling	16.3%	14.2%	(-2.1 p.p.)	15.2%	16.0%	0.8 p.p.
PDA	10.5%	9.6%	(-0.9 p.p.)	12.3%	10.4%	(-1.9 p.p.)

The decrease in General and Administrative Expenses, Selling, as well as PDA relative to Net Revenue in 3Q24, offset the increase in educational infrastructure expenses related to the expansion of hybrid courses, mainly in health and engineering.



Good control of SG&A and PDA resulting in EBITDA margin gains and capturing of operational leverage





The Adjusted EBITDA Margin increased by 0.4 p.p vs. 3Q23, driven by SG&A savings, mainly in the selling expenses line, combined with a good PDA performance.



Strong growth in Adjusted Net Income and net margin improvement



Adjusted Net Profit and Margin Breakdown of Adjusted Net Income (R\$MM) (R\$MM) **4**.6 p.p. 7.4% ***** 76.3% ▲ 76.3% | ▲ 4.6 p.p. Margin 64.1 64.1 21.9 18.2 3.1 36.3 22.6 36.3 (35.5) (2.5) 7.4% 12.1% Adj. Net Others⁽¹⁾ Adjusted Financial Depreciation Income 3023 3Q24 Corresponding Adj. Net Income **EBITDA** Result and Tax •••••• % of Net Revenue tax effects on Income. Amortization 3Q23 adjustments

3Q24



Cach flow

Maintaining strong levels of operational cash conversion



(R\$MM)							(R\$MM)			
R\$ million	3Q24	3Q23	% Chg	9M24	9M23	% Chg				
Adjusted EBITDA	202,5	184,3	9,9%	626,1	561,0	11,6%			▼ 0.2	ь р.р.
Non-recurring	(15,2)	(3,3)	353,8%	(43,5)	(23,9)	82,3%			5.9%	
Provisions	57,4	45,0	27,6%	157,6	161,8	(2,6)%				5.5%
Adjusted EBITDA for cash purposes	244,7	225,9	8,3%	740,2	698,9	5,9%				
Working capital variation	(64,3)	(28,1)	128,5%	(204,1)	(204,8)	(0,4)%			A 2	.7%
Accounts receivable	(44,4)	(57,2)	(22,3)%	(180,0)	(212,5)	(15,3)%	- 0.4	p.p.	-	••••
Accounts payable	(28,6)	22,1	n.a.	(29,1)	22,0	n.a.	6.5%	 7.0%	0.6	88.7
Others	8,7	6,9	26,1%	5,0	(14,3)	n.a.	0.570		86.4	00.7
Income Tax	(9,5)	(12,4)	(23,7)%	(37,8)	(32,1)	17,9%				
Lease payments	(14,9)	(14,4)	3,8%	(44,2)	(42,0)	5,2%				
Other operating activities	(4,6)	13,5	n.a.	(25,6)	5,0	n.a.	1 6	5.2%		
Operational Cash Flow	151,4	184,5	(17,9)%	428,7	425,0	0,9%				
Operational Cash Flow Conversion	61,9%	81,7%	(19,8) p.p.	57,9%	60,8%	(2,9) p.p.		27.0		
Сарех	(37,0)	(31,8)	16,4%	(88,7)	(86,4)	2,7%	31.8	37.0		
Free Cash Flow	114,4	152,6	(25,0)%	340,0	338,7	0,4%	J			
Financial Results	(20,2)	13,3	n.a.	(155,2)	(107,2)	44,7%				
Receivables anticipation	_	21,0	(100,0)%	-	21,0	(100,0)%				
Acquisitions or divestments of assets	(18,8)	-	n.a.	(18,8)	-	n.a.				
Total cash flow	75,4	186,9	(59,6)%	166,0	252,4	(34,2)%				
(generation/consumption)							3Q23	3Q24	9M23	9M24


Accounts payable reflects one-off effects related to the advancement of marketing funds to partners in 3Q24, as well as the payment for the migration to B3 and the base effect from the displacement of suppliers between 3Q and 4Q23.


Total cash generation, after debt service, showed some non-recurring effects, such as the one-off payment of interest on the first issue of debentures, which was paid off early.

CADEY

We remain fully focused on deleveraging, reaching a level of 2.4x Net Debt / Adjusted EBITDA in 3Q24.







(1) Does not consider leasing liabilities; (2) Adjusted EBITDA Ex-IFRS-16; (3) Already includes the 4th issue of debentures in the amortization schedule.



Q&A

To ask a question, please click the "Q&A" icon at the bottom of the screen to join the queue. If announced, a request to activate your microphone will show up on your screen; then you should enable your audio to ask your question.

"

04 Appendix 🔆









* Net Revenue

- * between R\$2.15 and R\$2.25 billion
- * growth between ~10% and ~15% vs. 2023

* Adjusted EBITDA Margin

- * between 36.5% and 37.5%
- * Compared to 36.6% in 2023

(1) Already considering the new criteria for activating students at UNIASSELVI and the respective impact on the DRE.





R\$ millions	3Q24	3Q23	9M24	9M23
Net income for the period	24.0	(1.9)	94.3	147.7
(+) M&A, pre-offering expenses and restructuring expenses	5.1	27.3	43.5	52.6
(+) Share-based compensation plan	0.3	(3.6)	3.8	(5.0)
(+) Amortization of intangible assets from business combinations	31.5	31.5	94.6	94.1
(+) Interest accrued on accounts payable from the acquisition of subsidiaries	-	1.8	-	5.9
(-) Corresponding tax effects on adjustments	3.1	(18.8)	(32.6)	(48.2)
Adjusted Net Income	64.1	36.3	203.6	247.1





R\$ millions	3Q24	3Q23	9M24	9M23	
Net income for the period	24.0	(1.9)	94.3	147.7	
(+) Deferred and current income tax	11.6	34.2	23.0	(20.9)	
(+) Financial result	101.5	66.0	287.4	204.2	
(+) Depreciation and amortization	53.5	50.9	160.9	156.9	
(+) Interest on tuition fees paid in arrears	5.6	6.9	11.8	20.5	
(+) Share-based compensation plan	0.3	(3.6)	3.8	(5.0)	
(+) Other income (expenses), net	0.8	4.4	1.5	5.1	
(+) M&A, pre-offering expenses and restructuring expenses	5.1	27.3	43.5	52.6	
Adjusted EBITDA	202.5	184.3	626.1	561.0	



<u>investors.vitru.com.br</u> ir@vitru.com.br

